CELU

Celularity Inc. is a clinical-stage biotechnology company developing off-the-shelf cellular therapies derived from the postpartum human placenta, headquartered in Florham Park, New Jersey. The company's technology platform utilizes placental tissue to create allogeneic cell therapies that may be used across multiple patients without requiring individual customization. Celularity's pipeline includes product candidates for hematologic malignancies, solid tumors, infectious diseases, and degenerative diseases. The company is advancing several clinical programs, including treatments for acute myeloid leukemia and COVID-19. Celularity's approach leverages the unique properties of placental cells, which have immunomodulatory and regenerative capabilities. The company aims to develop scalable, accessible cellular therapies that can address significant unmet medical needs while reducing manufacturing complexity compared to autologous cell therapies.